Form 8-K Adaptimmune Therapeutics For: Aug 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Adaptimmune Therapeutics (ADAP) Tops Q2 EPS by 16c
August 8, 2016 7:03 AM EDTAdaptimmune Therapeutics (NASDAQ: ADAP) reported Q2 EPS of ($0.05), $0.16 better than the analyst estimate of ($0.21).
For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.
... More
